JPWO2023076485A5 - - Google Patents
Info
- Publication number
- JPWO2023076485A5 JPWO2023076485A5 JP2024522407A JP2024522407A JPWO2023076485A5 JP WO2023076485 A5 JPWO2023076485 A5 JP WO2023076485A5 JP 2024522407 A JP2024522407 A JP 2024522407A JP 2024522407 A JP2024522407 A JP 2024522407A JP WO2023076485 A5 JPWO2023076485 A5 JP WO2023076485A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- compound
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263224P | 2021-10-28 | 2021-10-28 | |
| US63/263,224 | 2021-10-28 | ||
| PCT/US2022/048037 WO2023076485A1 (en) | 2021-10-28 | 2022-10-27 | Combination therapies comprising wee1 inhibitors and dna damage response (ddr) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024539872A JP2024539872A (ja) | 2024-10-31 |
| JPWO2023076485A5 true JPWO2023076485A5 (https=) | 2025-11-05 |
| JP2024539872A5 JP2024539872A5 (https=) | 2025-11-05 |
Family
ID=86158503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522407A Pending JP2024539872A (ja) | 2021-10-28 | 2022-10-27 | Ｗｅｅ１阻害剤及びｄｎａ損傷応答（ｄｄｒ）阻害剤を含む併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240299395A1 (https=) |
| EP (1) | EP4422624A4 (https=) |
| JP (1) | JP2024539872A (https=) |
| CN (1) | CN118234493A (https=) |
| TW (1) | TW202333729A (https=) |
| WO (1) | WO2023076485A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| BR112023000350A2 (pt) | 2020-07-09 | 2023-03-28 | Recurium Ip Holdings Llc | Sais e formas de um inibidor de wee1 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| WO2025186213A1 (en) * | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| EP2755482B1 (en) * | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combination of mk-1775 and mk-8776 for treating cancer |
-
2022
- 2022-10-27 WO PCT/US2022/048037 patent/WO2023076485A1/en not_active Ceased
- 2022-10-27 CN CN202280066997.3A patent/CN118234493A/zh active Pending
- 2022-10-27 TW TW111140882A patent/TW202333729A/zh unknown
- 2022-10-27 EP EP22888179.3A patent/EP4422624A4/en active Pending
- 2022-10-27 JP JP2024522407A patent/JP2024539872A/ja active Pending
-
2024
- 2024-04-26 US US18/648,164 patent/US20240299395A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104066731B (zh) | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 | |
| EP3194382B1 (en) | Pyrazole derivatives as sgc stimulators | |
| RU2582679C2 (ru) | СТИМУЛЯТОРЫ sGC | |
| ES2743699T3 (es) | Forma de dosificación oral de ketamina | |
| RU2430099C2 (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
| CN103917231B (zh) | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 | |
| JP2005533860A5 (https=) | ||
| JP2021513981A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2004520292A5 (https=) | ||
| US20160311826A1 (en) | Sgc stimulators | |
| JP2011510014A5 (https=) | ||
| CN101616917A (zh) | 吡啶并[2,3-d]嘧啶以及它们作为激酶抑制剂的用途 | |
| SG184721A1 (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
| JP2011524896A5 (https=) | ||
| WO2017136515A1 (en) | Chemicals and methods to prevent and treat tgf-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis | |
| EP2822560A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
| JP2021530525A (ja) | ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド | |
| JP5941258B2 (ja) | 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール | |
| JPWO2023076485A5 (https=) | ||
| US20150320749A1 (en) | IMMEDIATE RELEASE 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide FORMULATION | |
| JP2006512321A5 (https=) | ||
| CN117482102A (zh) | 使用5′-腺苷二磷酸核糖(adpr)的方法 | |
| TW201325594A (zh) | 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物 | |
| JP2010070514A (ja) | ピラゾール誘導体及びその医薬用途 |